Research Topics
| D R LowySummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Papillomaviruses: prophylactic vaccine prospectsD R Lowy
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
Biochim Biophys Acta 1423:M1-8. 1999..Since prospective efficacy trials will take several years to complete, considering alternative approaches is also worthwhile...
Prophylactic human papillomavirus vaccinesDouglas R Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
J Clin Invest 116:1167-73. 2006..Unresolved issues include the most critical groups to vaccinate and when the vaccine's cost may be low enough for widespread implementation in the developing world, where 80% of cervical cancer occurs...- Papillomavirus-like particle based vaccines: cervical cancer and beyondJ T Schiller
National Cancer Institute, Bethesda, MD, USA
Expert Opin Biol Ther 1:571-81. 2001..Vaccines based on this approach could potentially be effective alternatives to monoclonal antibody (mAb)-based therapies for a variety of disease targets... - Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenicR Kirnbauer
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Proc Natl Acad Sci U S A 89:12180-4. 1992..This type of L1 preparation might be considered as a candidate for a serological test to measure antibodies to conformational virion epitopes and for a vaccine to prevent papillomavirus infection... - L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidationM M Okun
Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
J Virol 75:4332-42. 2001..We conclude that the L1-binding domain located near the C terminus of L2 may bind L1 prior to completion of capsid assembly, and that both L1-binding domains of L2 are required for efficient encapsidation of the viral genome... - Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopesR B Roden
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4040, USA
Virology 270:254-7. 2000..This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection... - Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitopeR B Roden
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
J Virol 71:6247-52. 1997..E70 to L1 virus-like particles of the two variants. A substitution at residue 282 of L1 was responsible for this differential reactivity, suggesting that this residue constitutes part of the H16.E70 epitope... - The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylationM S Barbosa
Laboratory of Cellular Oncology, National Cancer Institute, NIH Bethesda, MD 20892
EMBO J 9:153-60. 1990.... - Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogeneT J Velu
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892
Science 238:1408-10. 1987.... - The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptorsP Martin
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
Cell 59:21-32. 1989..We conclude that E5 may enhance the receptor activity via inhibition of receptor down-modulation... - Papillomavirus-like particles induce acute activation of dendritic cellsP Lenz
Laboratory of Cellular Oncology, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 166:5346-55. 2001..These results offer a mechanistic explanation for the striking ability of papillomavirus VLP-based vaccines to induce potent T and B cell responses even in the absence of adjuvant... - NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16D V Pastrana
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, 20892, USA
Virology 279:361-9. 2001..Vaccination with HPV16 114K L1 VLPs generates antibodies that should confer a similar degree of protection against all known phylogenetic branches of HPV16... - Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteinsR M Melillo
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
Mol Cell Biol 14:8241-9. 1994.... - E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPasesL Asnaghi
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Oncogene 29:2760-71. 2010..These proteins can be considered downstream effectors of E-cadherin and might represent therapeutic targets in some NSCLC... - Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivoT J Velu
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
J Virol 63:1384-92. 1989.... - Identification of small clusters of divergent amino acids that mediate the opposing effects of ras and Krev-1K Zhang
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892
Science 249:162-5. 1990..Because this region in Ras proteins has been implicated in effector function, the results suggest that Krev-1 suppresses ras-induced transformation by interfering with interaction of Ras with its effector... - In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potentialM S Barbosa
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
J Virol 65:292-8. 1991..These same factors may, in part, account for the apparent difference in oncogenic potential between these viruses... - Selective potentiation of c-fps/fes transforming activity by a phosphatase inhibitorR A Feldman
Laboratory of Cellular Oncology National Cancer Institute, Bethesda, Maryland 20892
Oncogene Res 5:187-97. 1990..The specificity of the biological response of c-fps/fes to the stabilization of phosphotyrosine suggests that this molecule has a distinct mode of regulation and mechanism of action... - Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodiesB Chackerian
Laboratory of Cellular Oncology, National Institutes of Health, Bethesda, Maryland 20892-4040, USA
J Clin Invest 108:415-23. 2001..Together, these results suggest a potentially flexible method to efficiently generate autoantibodies against specific self-proteins that mediate arthritis and other diseases... - N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domainsX Qian
Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
Mol Cell Biol 18:771-8. 1998..We conclude that the Dbl and PH domains are critical for Sos function and that stable association of Sos with activated EGF receptors requires both the Sos N and C termini... - Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of RafP H Anborgh
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
Mol Cell Biol 19:4611-22. 1999.... 
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated womenTroy J Kemp
HPV Immunology Laboratory, SAIC Frederick Inc, NCI Frederick, Building 469, Room 120, Frederick, MD 21702, USA
Vaccine 26:3608-16. 2008....- Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infectionRebecca M Richards
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 103:1522-7. 2006..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition... - Human alpha-defensins block papillomavirus infectionChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD 20892-4263, USA
Proc Natl Acad Sci U S A 103:1516-21. 2006.... - Carrageenan is a potent inhibitor of papillomavirus infectionChristopher B Buck
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA
PLoS Pathog 2:e69. 2006..Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs... - Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesLigia A Pinto
HPV Immunology Laboratory, SAIC-Frederick, Inc./NCI-Frederick, Frederick Building 469, Room 120, Frederick, MD 21702, USA
Virology 353:451-62. 2006..In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from heterologous HPV types, suggesting the presence of conserved T cell epitopes... - Chapter 12: Prophylactic HPV vaccines: underlying mechanismsMargaret Stanley
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK
Vaccine 24:S3/106-13. 2006..Important issues remaining to be addressed include the duration of protection and genotype replacement... - Prospects for cervical cancer prevention by human papillomavirus vaccinationJohn T Schiller
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 66:10229-32. 2006..These include duration of protection, degree of cross-protection against nonvaccine types, efficacy in men, and vaccine availability to economically disadvantaged women... - Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibitionPatricia M Day
Laboratory of Cellular Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
J Virol 81:8784-92. 2007..We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes... - Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particlesAlfonso Garcia Pineres
HPV Immunology Laboratory, SAIC Frederick, Inc NCI Frederick, Frederick, Maryland 21702, USA
Clin Vaccine Immunol 14:984-9. 2007..Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV... - Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trialAllan Hildesheim
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
JAMA 298:743-53. 2007..Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and development of cervical precancers and cancer. Women with oncogenic HPV infections might consider vaccination as therapy... - Arrangement of L2 within the papillomavirus capsidChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
J Virol 82:5190-7. 2008..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle... - Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodiesTroy J Kemp
HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
Clin Vaccine Immunol 15:60-4. 2008..2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix... - Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodiesPatricia M Day
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 82:4638-46. 2008..These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines... - Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
Virology 337:365-72. 2005..BPV1 L2 was exceptionally effective at inducing cross-neutralizing antibodies to these shared epitopes... - Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccineDenise Nardelli-Haefliger
Department of Gynecology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
Vaccine 23:3634-41. 2005..Our data suggest that aerosol administration of HPV VLPs may represent a potential alternative to parenteral injection... - HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole bloodLigia A Pinto
SAIC Frederick, Inc NCI Frederick, Room 120, Building 469, Frederick, MD 21702, USA
Vaccine 23:3555-64. 2005.... - Papillomaviruses infect cells via a clathrin-dependent pathwayPatricia M Day
Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Building 36, Room 1D-32, Bethesda, MD 20892, USA
Virology 307:1-11. 2003..Surprisingly, the kinetics of internalization were unusually slow for this mechanism, with the t(1/2) of entry of BPV-1 being approximately 4 h versus 5-15 min for a typical ligand... - p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREBShuling Zhang
Laboratory of Genetics, Center for Cancer Research, Bethesda, MD 20892 4255, USA
Oncogene 22:2285-95. 2003..BALB/c mice have both regulatory and coding region defects that may contribute to the impairment of p16 gene function... - Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cellsPetra Lenz
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4040, USA
Clin Immunol 106:231-7. 2003..Our results indicate that VLPs target multiple cells of the immune system, which helps to account for VLPs being so effective in priming humoral and cellular immune responses even in the absence of adjuvant... - Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesLigia A Pinto
SAIC Frederick, Inc National Cancer Institute, Building 469, Room 120, Frederick, MD 21702, USA
J Infect Dis 188:327-38. 2003..Future efficacy studies are needed to evaluate whether and/or how VLP vaccines confer protection against genital HPV infection and associated disease... - Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particlesDenise Nardelli-Haefliger
Department of Gynecology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J Natl Cancer Inst 95:1128-37. 2003.... - A new link between Fanconi anemia and human papillomavirus-associated malignanciesDouglas R Lowy
J Natl Cancer Inst 95:1648-50. 2003 - Efficient intracellular assembly of papillomaviral vectorsChristopher B Buck
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892-4263, USA
J Virol 78:751-7. 2004..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism... - Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virusBryce Chackerian
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 78:4037-47. 2004.... - Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cellsPetra Lenz
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA
Eur J Immunol 35:1548-56. 2005..Finally, CpG-activated pDC, but not pDC exposed to HPV16 VLP, activated lymphocytes to secrete IL-10 and low levels of IFN-gamma. Together these findings suggest a possible immunogenic effect of pDC in the setting of VLP vaccination... - Maturation of papillomavirus capsidsChristopher B Buck
Laboratory of Cellular Oncology, Building 37, Room 4106, 9000 Rockville Pike, Bethesda, MD 20892-4263, USA
J Virol 79:2839-46. 2005..Despite their obvious morphological differences, mature and immature capsids are similarly neutralizable by various L1- and L2-specific antibodies... - Determinants of autoantibody induction by conjugated papillomavirus virus-like particlesBryce Chackerian
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 169:6120-6. 2002.... - Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expressionPatricia M Day
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 101:14252-7. 2004..The results identify a role for PML in the enhancement of viral infectivity in the early part of the life cycle. We propose a model in which L2 chaperones the viral genome to ND10 to efficiently initiate viral transcription... - Human papillomavirus infection and the primary and secondary prevention of cervical cancerDouglas R Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Cancer 113:1980-93. 2008..The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer... - Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Diana V Pastrana
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA
Virology 321:205-16. 2004..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies... - Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activitiesXiaolan Qian
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:9012-7. 2007..The results suggest that DLC1 is a multifunctional protein whose biological activity depends on cooperation between its tensin binding and RhoGAP activities, although neither activity depends on the other... - Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaRolando Herrero
Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, Torre La Sabana, 300 Oeste del ICE, Piso 7, Sabana Norte, San Jose, Costa Rica
Vaccine 26:4795-808. 2008..4% agreement for all types, kappa 0.59). Follow up will continue with yearly or more frequent examinations for at least 4 years for each participant... - Epidemiology of genital Chlamydia trachomatis infection among young women in Costa RicaCarolina Porras
Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, San Jose, Costa Rica
Sex Transm Dis 35:461-8. 2008..To investigate Chlamydia trachomatis (Ct) epidemiology among 5829 women 18 to 25 years old, in Costa Rica... - Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasisNigel P S Crawford
Laboratory of Population Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS Genet 3:e214. 2007..These data suggest that RRP1B may be a novel susceptibility gene for breast cancer progression and metastasis... - DLC-1:a Rho GTPase-activating protein and tumour suppressorMarian E Durkin
Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
J Cell Mol Med 11:1185-207. 2007..Two closely related genes, DLC-2 and DLC-3, may also be tumour suppressors. This review presents the current status of progress in understanding the biological functions of DLC-1 and its relatives and their roles in neoplasia... - Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenanJeffrey N Roberts
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4263, USA
Nat Med 13:857-61. 2007..In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide... - Generation of HPV pseudovirions using transfection and their use in neutralization assaysChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Methods Mol Med 119:445-62. 2005..Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA)... - Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1Yeong Gwan Park
Laboratory of Population Genetics, National Cancer Institute, Building 41, Room 702, 41 Library Drive, Bethesda, Maryland 20892, USA
Nat Genet 37:1055-62. 2005..This report is also the first demonstration, to our knowledge, of a constitutional genetic polymorphism affecting tumor metastasis... - E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinasesXiaolan Qian
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
EMBO J 23:1739-48. 2004..Abrogation of E-cadherin regulation may contribute to the frequent ligand-dependent activation of RTK in tumors... - Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E-cadherin/beta-catenin activityShaowei Li
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Mol Carcinog 37:98-109. 2003..We conclude that the hamartin/tuberin complex exerted a direct effect on the morphology and adhesive properties of 293 cells through regulation of the level and/or activity of cellular E-cadherin/beta-catenin...